X

Trial Profile

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Jun 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Retifanlimab (Primary)
Indications Cervical cancer; Endometrial cancer; Non-small cell lung cancer; Sarcoma; Solid tumours
Focus Adverse reactions
Acronyms POD1UM-101
Sponsors Incyte Corporation; MacroGenics

Most Recent Events

11 Jun 2024 Status changed from active, no longer recruiting to completed.
24 Oct 2023 Final results from the POD1UM-101 study (Cohort H, n=76) presented at the 48th European Society for Medical Oncology Congress.
16 Oct 2023 According to Incyte media release, final results from this study will be presented t the upcoming European Society for Medical Oncology (ESMO) Congress 2023, held October 20-24 in Madrid.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com